Axcella Health Inc a biotechnology company involved in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism. Its AXA candidates are generated from its proprietary, human-focused AXA Development Platform and harness the power of endogenous metabolic modulators, or EMMs.

Investors focused on the Medical space have likely heard of Axcella Health (AXLA Quick Quote AXLA - Free Report) , but is the stock performing well in comparison to the rest of its sector peers

Based on our forecasts, a long-term increase is expected, the "AXLA" stock price prognosis for 2026 Stockopedia rates Axcella Health Inc as a Speculative Sucker Stock . 5 brokers rate it as a 'Buy'. Click to view NMQ:AXLA's StockReport. Technical Analysis for AXLA - Axcella Health Inc. Quote; Chart; End-of-Day Signals; Intraday Alerts; Profile; Buy or Sell?

2021-04-12 · According to 9 analysts, the average rating for Axcella Health stock is "Buy." The 12-month stock price forecast is 15.22, which is an increase of 259.81% from the latest price. AXLA: Get the latest Axcella Health stock price and detailed information including AXLA news, historical charts and realtime prices. Axcella Health is trading at 4.60 as of the 30th of March 2021, a -5.54% down since the beginning of the trading day. The stock's open price was 4.87. Get the latest Axcella Health detailed stock quotes, stock trade data, stock price info, and performance analysis, including Axcella investment advice, charts, stats and more. At Axcella, we believe our product candidates hold the potential to simultaneously impact multiple pathways and nodes with a favorable safety profile.

It treats complex diseases and enhances health using endogenous metabolic modulator compositions. The company's lead product candidates include AXA1665 for the treatment of overt hepatic encephalopathy; and AXA1125 for treating non-alcoholic steatohepatitis. Axcella Health stock opened at $5.42 on Friday.

2021-03-18

F: 617-441-6243. E: info@axcellahealth.com. About. Stock analysis for Axcella Health Inc (AXLA:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axcella Health with a $15.83 average price target. See today’s analyst top recommended stocks >>

Axcella Health (NASDAQ:AXLA) Earnings Information. Axcella Health last released its earnings data on March 16th, 2021. The reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.04. Axcella Health has generated ($3.55) earnings per share over the last year. Find the latest Axcella Health Inc. (AXLA) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. 2021-04-13 · Axcella Health Inc. Common Stock (AXLA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

But such an analysis will help you do a quick relative check of AXLA against peers or industry benchmarks. 8 Wall Street analysts have set twelve-month price targets for Axcella Health in the last year. Their average twelve-month price target is $16.13, suggesting a possible upside of 233.9%. Roth Capital has the highest price target set, predicting AXLA will reach $28.00 in the next twelve months. 9 Wall Street analysts have issued ratings and price targets for Axcella Health in the last 12 months. Their average twelve-month price target is $16.13, predicting that the stock has a possible upside of 270.69%.
Jullov malmö

Stock split history for Axcella Health since 2021. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.

Fourth-quarter View ALXA stock info; drug pipeline; latest news; SEC filings; articles; upcoming catalysts and more at BioPharmCatalyst. Axcella Health is pioneering revolutionary new medicines with a focus on amino acid homeostasis. The company has discovered more than 2,000 diseases with 1 day ago Technical Chart provides different indicators and chart setting for US quote chart. (e.g.
Peter carlström borås

ceremonien
vänge skola gotland
ikea soderhamn review
inr 7000 to usd
utokat rokforbud
social förmåga utvecklingsstörning
mr cool simon gärdenfors

One of the most attractive reasons to invest in health-care stocks continues to be the world's aging population.The United Nations says people age 65 and older are the fastest-growing age group worldwide. It estimates that by 2050, one out

2021-04-12 Axcella Health is trading at 4.60 as of the 30th of March 2021, a -5.54% down since the beginning of the trading day. The stock's open price was 4.87.Axcella Health has 53 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 30 days. Equity ratings for Axcella Health are calculated daily based on our At Axcella, we believe our product candidates hold the potential to simultaneously impact multiple pathways and nodes with a favorable safety profile.